UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Clinical cancer research, 2016-05, Vol.22 (10), p.2351-2358

2016

Volltextzugriff (PDF)

Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain

Scientific reports, 2024-09, Vol.14 (1), p.22191-14, Article 22191

2024

Volltextzugriff (PDF)

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

Proceedings of the National Academy of Sciences - PNAS, 2015-09, Vol.112 (39), p.E5381-E5390

2015

Volltextzugriff (PDF)

Subtle sequence variations alter tripartite complex kinetics and G-quadruplex dynamics in RNA aptamer Broccoli

Chemical communications (Cambridge, England), 2020-02, Vol.56 (17), p.2634-2637

2020

Volltextzugriff (PDF)

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins

Proceedings of the National Academy of Sciences - PNAS, 2013-11, Vol.110 (48), p.19519-19524

2013

Volltextzugriff (PDF)

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

Leukemia, 2018-11, Vol.32 (11), p.2374-2387

2018

Volltextzugriff (PDF)

Long-term potentiation-dependent spine enlargement requires synaptic Ca2+-permeable AMPA receptors recruited by CaM-kinase I

The Journal of neuroscience, 2010-09, Vol.30 (35), p.11565-11575

2010

Volltextzugriff (PDF)

Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma

Molecular cancer research, 2019-03, Vol.17 (3), p.676-685

2019

Volltextzugriff (PDF)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

EMBO molecular medicine, 2023-10, Vol.15 (10), p.e17367-e17367

2023

Volltextzugriff (PDF)

Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target

Proceedings of the National Academy of Sciences - PNAS, 2013-11, Vol.110 (48), p.19513-19518

2013

Volltextzugriff (PDF)

ROS1-dependent cancers — biology, diagnostics and therapeutics

Nature reviews. Clinical oncology, 2021-01, Vol.18 (1), p.35-55

2021

Volltextzugriff (PDF)

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Communications biology, 2020-12, Vol.3 (1), p.776-776, Article 776

2020

Volltextzugriff (PDF)

RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation

Disease models & mechanisms, 2021-02, Vol.14 (2)

2021

Volltextzugriff (PDF)

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

NPJ precision oncology, 2024-08, Vol.8 (1), p.175-11, Article 175

2024

Volltextzugriff (PDF)

Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

NPJ precision oncology, 2024-08, Vol.8 (1), p.184-1, Article 184

2024

Volltextzugriff (PDF)

Discovery and Validation of a Compound to Target Ewing's Sarcoma

Pharmaceutics, 2021-09, Vol.13 (10), p.1553

2021

Volltextzugriff (PDF)

Critical Role of cAMP-Dependent Protein Kinase Anchoring to the L-Type Calcium Channel Cav1.2 via A-Kinase Anchor Protein 150 in Neurons

Biochemistry (Easton), 2007-02, Vol.46 (6), p.1635-1646

2007

Volltextzugriff (PDF)

Functional impact and targetability of PI3KCA , GNAS , and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation

Cold Spring Harbor molecular case studies, 2022-01, Vol.8 (1), p.a006140

2022

Volltextzugriff (PDF)

Therapeutically Targetable ALK Mutations in Leukemia

Cancer research (Chicago, Ill.), 2015-06, Vol.75 (11), p.2146-2150

2015

Volltextzugriff (PDF)

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

Clinical cancer research, 2020-06, Vol.26 (11), p.2654-2663

2020

Volltextzugriff (PDF)

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors

Molecular cancer therapeutics, 2022-02, Vol.21 (2), p.336-346

2022

Volltextzugriff (PDF)

ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells

Molecular and cellular biochemistry, 2010-02, Vol.335 (1-2), p.155-171

2010

Volltextzugriff (PDF)

Revisiting NTRKs as an emerging oncogene in hematological malignancies

Leukemia, 2019-11, Vol.33 (11), p.2563-2574

2019

Volltextzugriff (PDF)

A Broccoli aptamer chimera yields a fluorescent K sensor spanning physiological concentrations

Chemical communications (Cambridge, England), 2021-02, Vol.57 (11), p.1344-1347

2021

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(112)
Dissertationen
(1)

Sprache

Englisch
(112)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(49)
Animals
(37)
Humans
(36)
Oncology
(24)
Rats
(20)
Mice
(17)
Cell Line, Tumor
(16)
Mutation
(15)
Phosphorylation
(15)
Kinases
(14)
Neurosciences
(13)
Neurosciences & Neurology
(12)
Rats, Sprague-Dawley
(12)
Cells, Cultured
(11)
Protein Kinase Inhibitors - Therapeutic Use
(10)
Proteins
(10)
Signal Transduction
(10)
Oncogene Proteins, Fusion - Genetics
(9)
Protein Kinase Inhibitors - Pharmacology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

Subtle sequence variations alter tripartite complex kinetics and G-quadruplex dynamics in RNA aptamer Broccoli

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

Long-term potentiation-dependent spine enlargement requires synaptic Ca2+-permeable AMPA receptors recruited by CaM-kinase I

Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target

ROS1-dependent cancers — biology, diagnostics and therapeutics

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

Discovery and Validation of a Compound to Target Ewing's Sarcoma

Critical Role of cAMP-Dependent Protein Kinase Anchoring to the L-Type Calcium Channel Cav1.2 via A-Kinase Anchor Protein 150 in Neurons

Functional impact and targetability of PI3KCA , GNAS , and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation

Therapeutically Targetable ALK Mutations in Leukemia

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors

ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells

Revisiting NTRKs as an emerging oncogene in hematological malignancies

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib

A Broccoli aptamer chimera yields a fluorescent K sensor spanning physiological concentrations

Suchergebnisse filtern